ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that: (i) Actinium “repeatedly touted the Sierra Trial’s positive DCR data while downplaying the study’s failure to generate statistically significant or clinically meaningful ...

-  99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models -  ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the develo ...

PALM BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts see the global radiotherapy market continuing to grow in the years to come. A recent report from MarketsAndMarkets said that the global radiotherapy market, which was valued at US$6.23 billion in 2022, grew at a robust CAGR of 4.9%, and reached US$7.21 billion in 2024 and is expected to reach an impressive US$9.62 billion by 2030. It said: "During the forecast years, the growth of the market is attributed ...

- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology - Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditi ...

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure - Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market - Presentation follows Investor KOL Event and Company Update on March 25th NEW YORK, March 2 ...

Core Insights - Actinium Pharmaceuticals is presenting three multi-billion-dollar market opportunities for its products Actimab-A and Iomab-ACT in the treatment of myeloid malignancies, solid tumors, and cell & gene therapy conditioning [1][2] Group 1: Actimab-A Developments - Actimab-A is being positioned as a mutation-agnostic backbone therapy for myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) across various treatment settings [2][3] - Clinical results for Actimab-A show high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity in relapsed/refractory AML patients, leading to improved survival outcomes [3][4] - A pivotal Phase 2/3 clinical trial for Actimab-A in relapsed/refractory AML is planned, along with trials under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) [1][3] Group 2: Solid Tumor Program - Actinium is advancing a solid tumor program for Actimab-A, which includes head-to-head clinical trials evaluating its combination with PD-1 inhibitors like KEYTRUDA and OPDIVO against these inhibitors alone [1][3] - The trials will initially focus on patients with head and neck squamous cell carcinoma and non-small cell lung cancer [1] Group 3: Iomab-ACT and Future Prospects - Iomab-ACT is being developed as a universal targeted conditioning agent to enhance patient access to cell and gene therapies and improve outcomes [2][3] - Actinium is also seeking a strategic partner for Iomab-B, which serves as an induction and conditioning agent prior to bone marrow transplant in patients with relapsed/refractory AML [4]

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidate ...

NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and me ...

-       Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes-       MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®-       Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33-       Clinical proof of concept data expected in 2025 could potentially open up ...

Core Insights - Actinium Pharmaceuticals has reported promising results from a clinical trial of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (r/r AML), showing a median overall survival of 18.4 months [1][5] - The combination therapy demonstrated high rates of complete remissions and measurable residual disease negativity, particularly in high-risk patients, indicating its mutation agnostic potential [1][3] - Actinium plans to initiate a pivotal Phase 2/3 trial to further evaluate the efficacy of Actimab-A + CLAG-M in r/r AML patients [3][4] Clinical Trial Results - The trial showed a median overall survival of 18.4 months for patients who had received 1 or 2 lines of prior therapy, compared to historical data showing a median survival of 13.3 months with CLAG-M alone [5] - 52% of patients in the trial had TP53 mutations, and 75% of all patients achieved measurable residual disease negativity [5] - Among patients with prior Venetoclax therapy, 100% achieved measurable residual disease negativity, highlighting the effectiveness of the combination therapy [5] Future Developments - Actinium has aligned with the FDA to conduct a pivotal Phase 2/3 trial, which will include a randomized comparison of Actimab-A + CLAG-M versus CLAG-M alone [3][4] - The trial aims to optimize the dosing of Actimab-A and is expected to begin in 2025 [3] - Actinium is also engaged in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to explore additional combinations for AML treatment [6]